Back to Search
Start Over
Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
- Source :
-
Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2024 Aug; Vol. 123 (8), pp. 875-881. Date of Electronic Publication: 2024 Jan 09. - Publication Year :
- 2024
-
Abstract
- Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression despite prior treatment with ALK tyrosine kinase inhibitors (TKIs) was assessed. Herein, we report real-world clinical outcomes of lorlatinib-treated patients with ALK-positive advanced NSCLC who were heavily pretreated and progressed on first- and second-generation ALK-TKIs, in a Taiwanese population under the lorlatinib expanded access program (EAP).<br />Methods: This multicenter observational study examined the effectiveness and safety of ALK-positive advanced NSCLC patients that progressed from previous second-generation ALK-TKI therapy and received lorlatinib treatment subsequently. Patients who received lorlatinib treatment under EAP between Jul 2017 and Sep 2019 were eligible. Patients were followed for at least one year from the first lorlatinib treatment until study completion.<br />Results: Sixty-three patients were eligible for safety analysis (male: 46.0 %; median age: 52.8 [27.5-78.3] years; brain metastases: 81.0 %). Fifty-four patients with more than one-month lorlatinib treatment were included in the effectiveness analysis. Prior to lorlatinib treatment, 10 patients (18.5 %) received one ALK-TKI, 27 (50.0 %) received two ALK-TKIs, and 17 (31.5 %) received three or more ALK-TKIs. The overall median rwPFS was 9.2 months (95 % confidence interval: 5.3-21.1). The best overall response rate (n = 51) was 13.7 %, with a disease control rate of 80.4 %.<br />Conclusion: Lorlatinib exhibits substantial activity and tolerability when used clinically in a later-line setting in a Taiwanese population with ALK-positive advanced NSCLC.<br />Competing Interests: Declaration of competing interest A conflict of interest occurs when an individual's objectivity is potentially compromised by a desire for financial gain, prominence, professional advancement or a successful outcome. JFMA Editors strive to ensure that what is published in the Journal is as balanced, objective and evidence-based as possible. Since it can be difficult to distinguish between an actual conflict of interest and a perceived conflict of interest, the Journal requires authors to disclose all and any potential conflicts of interest.<br /> (Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Taiwan
Adult
Protein Kinase Inhibitors therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Anaplastic Lymphoma Kinase antagonists & inhibitors
Aminopyridines therapeutic use
Lactams therapeutic use
Pyrazoles therapeutic use
Lactams, Macrocyclic therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0929-6646
- Volume :
- 123
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Journal of the Formosan Medical Association = Taiwan yi zhi
- Publication Type :
- Academic Journal
- Accession number :
- 38195317
- Full Text :
- https://doi.org/10.1016/j.jfma.2023.12.019